Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results

Nuvation Bio (NYSE:NUVB) released its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Zacks reports. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The company had revenue of $31.69 million during the quarter, compared to analyst estimates of $27.03 million.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI net revenue rose 25% quarter over quarter to $23.2 million, with approximately 160 new patient starts; 85% were in the first-line setting, up from roughly 30% at launch. Management said IBTROZI is now the ROS1 TKI market leader in first-line and overall new patient starts.
• Management highlighted IBTROZI’s reported 90% response rate and 50-month median duration of response in TKI-naive patients, along with low adverse-event discontinuations and no CNS warning on its label. The company believes these characteristics are driving broad adoption across academic, community, and integrated delivery network accounts.
• Nuvation expanded safusidenib development across all major IDH1-mutant glioma segments, including a new Phase III study in newly diagnosed low-grade disease and a Phase II study in patients whose disease progresses after vorasidenib. In updated J201 data, the response rate increased to 52%, while the 36-month progression-free survival rate was 79%.
• The company ended the quarter with $661 million in cash, cash equivalents, and marketable securities and raised approximately $279 million through low-coupon convertible notes. Management said the financing reduced cash interest expense, strengthened strategic flexibility, and should provide sufficient capital to reach profitability and fund the anticipated safusidenib launch.
• Later-line IBTROZI patient additions are slowing as the company has largely worked through the finite pool of pretreated patients, making future growth increasingly dependent on first-line adoption, improved testing, and converting patients who still receive chemotherapy or immunotherapy.

Nuvation Bio Price Performance

Shares of NYSE:NUVB traded up $0.31 during trading on Friday, hitting $6.42. 2,405,745 shares of the stock were exchanged, compared to its average volume of 5,546,931. The company has a market cap of $2.23 billion, a PE ratio of -14.99 and a beta of 1.52. The company has a current ratio of 7.44, a quick ratio of 7.24 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $5.72 and a two-hundred day moving average price of $5.23. Nuvation Bio has a 12-month low of $2.18 and a 12-month high of $9.75.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NUVB. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research note on Wednesday, June 10th. Truist Financial boosted their target price on Nuvation Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research note on Thursday, July 23rd. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada set a $20.00 target price on Nuvation Bio in a report on Friday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Nuvation Bio currently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Insider Transactions at Nuvation Bio

In related news, Director Robert Mashal purchased 25,000 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was bought at an average price of $4.73 per share, with a total value of $118,250.00. Following the completion of the transaction, the director owned 225,000 shares of the company’s stock, valued at approximately $1,064,250. This represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kerry Wentworth sold 63,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.02, for a total value of $379,260.00. Following the completion of the transaction, the insider directly owned 53,000 shares of the company’s stock, valued at approximately $319,060. This trade represents a 54.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 235,668 shares of company stock worth $1,419,495. Corporate insiders own 30.11% of the company’s stock.

Institutional Trading of Nuvation Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. bought a new position in shares of Nuvation Bio in the third quarter valued at approximately $55,000. Mackenzie Financial Corp raised its holdings in Nuvation Bio by 38.8% during the third quarter. Mackenzie Financial Corp now owns 15,746 shares of the company’s stock worth $58,000 after purchasing an additional 4,400 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Nuvation Bio by 19,876.0% during the third quarter. Russell Investments Group Ltd. now owns 20,775 shares of the company’s stock worth $77,000 after purchasing an additional 20,671 shares in the last quarter. Merit Financial Group LLC acquired a new stake in Nuvation Bio in the third quarter worth approximately $55,000. Finally, Man Group plc acquired a new stake in Nuvation Bio in the second quarter worth approximately $75,000. 61.67% of the stock is owned by hedge funds and other institutional investors.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.